A novel anti-inflammatory role of GPR120 in intestinal epithelial cells

American Journal of Physiology - Cell Physiology

Volumn 310, Issue 7, 2016, Pages C612-C621

  Anbazhagan, Arivarasu N ^a   Priyamvada, Shubha ^a   Gujral, Tarunmeet ^a   Bhattacharyya, Sumit ^a   Alrefai, Waddah A ^a,b   Dudeja, Pradeep K ^a,b   Borthakur, Alip ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

Caco 2; FFAR4; GLP 1; NF B; STC 1

Indexed keywords

BETA ARRESTIN 2; DOCOSAHEXAENOIC ACID; G PROTEIN COUPLED RECEPTOR 120; GLUCAGON LIKE PEPTIDE 1; GW 9508; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROTEIN; SMALL INTERFERING RNA; TUG 891; UNCLASSIFIED DRUG; G PROTEIN COUPLED RECEPTOR; O3FAR1 PROTEIN, HUMAN; O3FAR1 PROTEIN, MOUSE; O3FAR1 PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CACO 2 CELL LINE; CELL LINE; CELL SPECIFICITY; CELLS BY BODY ANATOMY; CONTROLLED STUDY; ENDOCRINE CELL; GENE SILENCING; HUMAN; HUMAN CELL; INTERNALIZATION; INTESTINE EPITHELIUM CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS; RAT; ANIMAL; C57BL MOUSE; CACO-2 CELL LINE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC TRANSFECTION; IMMUNOBLOTTING; IMMUNOLOGY; IMMUNOPRECIPITATION; INFLAMMATION; INTESTINE MUCOSA; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT;

ANIMALS; CACO-2 CELLS; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; INFLAMMATION; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED C57BL; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, G-PROTEIN-COUPLED; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84983801504     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00123.2015     Document Type: Article

References (28)

1. Atreya I, Atreya R, Neurath MF. NF-kappaB in inflammatory bowel disease. J Intern Med 263: 591–596, 2008.
2. Bassaganya-Riera J, Hontecillas R. Dietary conjugated linoleic acid and n-3 polyunsaturated fatty acids in inflammatory bowel disease. Curr Opin Clin Nutr Metab Care 13: 569–573, 2010.
3. Borthakur A, Bhattacharyya S, Kumar A, Anbazhagan AN, Tobacman JK, Dudeja PK. Lactobacillus acidophilus alleviates platelet-activating factor-induced inflammatory responses in human intestinal epithelial cells. PLoS One 8: e75664, 2013.
4. Borthakur A, Gill RK, Tyagi S, Koutsouris A, Alrefai WA, Hecht GA, Ramaswamy K, Dudeja PK. The probiotic Lactobacillus acidophilus stimulates chloride/hydroxyl exchange activity in human intestinal epithelial cells. J Nutr 138: 1355–1359, 2008.
5. Borthakur A, Saksena S, Gill RK, Alrefai WA, Ramaswamy K, Dudeja PK. Regulation of monocarboxylate transporter 1 (MCT1) promoter by butyrate in human intestinal epithelial cells: Involvement of NF-kappaB pathway. J Cell Biochem 103: 1452–1463, 2008.
6. Calder PC. Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. Biochim Biophys Acta 1851: 469–484, 2015.
7. Chimerel C, Emery E, Summers DK, Keyser U, Gribble FM, Reimann F. Bacterial metabolite indole modulates incretin secretion from intestinal enteroendocrine L cells. Cell Rep 9: 1202–1208, 2014.
8. Diakogiannaki E, Gribble FM, Reimann F. Nutrient detection by incretin hormone secreting cells. Physiol Behav 106: 387–393, 2012.
9. Druart C, Neyrinck AM, Vlaeminck B, Fievez V, Cani PD, Delzenne NM. Role of the lower and upper intestine in the production and absorption of gut microbiota-derived PUFA metabolites. PLoS One 9: e87560, 2014.
10. Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, Sugimoto Y, Miyazaki S, Tsujimoto G. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 11: 90–94, 2005.
11. Hudson BD, Shimpukade B, Mackenzie AE, Butcher AJ, Pediani JD, Christiansen E, Heathcote H, Tobin AB, Ulven T, Milligan G. The pharmacology of TUG-891, a potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120), demonstrates both potential opportunity and possible challenges to therapeutic agonism. Mol Pharmacol 84: 710–725, 2013.
12. Hudson BD, Shimpukade B, Milligan G, Ulven T. The molecular basis of ligand interaction at free fatty acid receptor 4 (FFA4/GPR120). J Biol Chem 289: 20345–20358, 2014.
13. Ichimura A, Hara T, Hirasawa A. Regulation of energy homeostasis via GPR120. Front Endocrinol (Lausanne) 5: 111, 2014.
14. Ichimura A, Hasegawa S, Kasubuchi M, Kimura I. Free fatty acid receptors as therapeutic targets for the treatment of diabetes. Front Pharmacol 5: 236, 2014.
15. Iwasaki K, Harada N, Sasaki K, Yamane S, Iida K, Suzuki K, Hamasaki A, Nasteska D, Shibue K, Joo E, Harada T, Hashimoto T, Asakawa Y, Hirasawa A, Inagaki N. Free fatty acid receptor GPR120 is highly expressed in enteroendocrine K cells of the upper small intestine and has a critical role in GIP secretion after fat ingestion. Endocrinology 156: 837–846, 2015.
16. Jeon MK, Klaus C, Kaemmerer E, Gassler N. Intestinal barrier: molecular pathways and modifiers. World J Gastrointest Pathophysiol 4: 94–99, 2013.
17. Katsuma S, Hatae N, Yano T, Ruike Y, Kimura M, Hirasawa A, Tsujimoto G. Free fatty acids inhibit serum deprivation-induced apoptosis through GPR120 in a murine enteroendocrine cell line STC-1. J Biol Chem 280: 19507–19515, 2005.
18. Mo XL, Wei HK, Peng J, Tao YX. Free fatty acid receptor GPR120 and pathogenesis of obesity and type 2 diabetes mellitus. Prog Mol Biol Transl Sci 114: 251–276, 2013.
19. Mobraten K, Haug TM, Kleiveland CR, Lea T. Omega-3 and omega-6 PUFAs induce the same GPR120-mediated signalling events, but with different kinetics and intensity in Caco-2 cells. Lipids Health Dis 12: 101, 2013.
20. Oh DY, Walenta E, Akiyama TE, Lagakos WS, Lackey D, Pessentheiner AR, Sasik R, Hah N, Chi TJ, Cox JM, Powels MA, Di Salvo J, Sinz C, Watkins SM, Armando AM, Chung H, Evans RM, Quehenberger O, McNelis J, Bogner-Strauss JG, Olefsky JM. A Gpr120- selective agonist improves insulin resistance and chronic inflammation in obese mice. Nat Med 20: 942–947, 2014.
21. Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, Li P, Lu WJ, Watkins SM, Olefsky JM. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142: 687–698, 2010.
22. Paulsen SJ, Larsen LK, Hansen G, Chelur S, Larsen PJ, Vrang N. Expression of the fatty acid receptor GPR120 in the gut of diet-inducedobese rats and its role in GLP-1 secretion. PLoS One 9: e88227, 2014.
23. Talukdar S, Olefsky JM, Osborn O. Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases. Trends Pharmacol Sci 32: 543–550, 2011.
24. van der Flier LG, Clevers H. Stem cells, self-renewal, and differentiation in the intestinal epithelium. Annu Rev Physiol 71: 241–260, 2009.
25. Wellhauser L, Belsham DD. Activation of the omega-3 fatty acid receptor GPR120 mediates anti-inflammatory actions in immortalized hypothalamic neurons. J Neuroinflammation 11: 60, 2014.
26. Williams-Bey Y, Boularan C, Vural A, Huang NN, Hwang IY, Shan- Shi C, Kehrl JH. Omega-3 free fatty acids suppress macrophage inflammasome activation by inhibiting NF-kappaB activation and enhancing autophagy. PLoS One 9: e97957, 2014.
27. Wullaert A. Role of NF-kappaB activation in intestinal immune homeostasis. Int J Med Microbiol 300: 49–56, 2010.
28. Zhang D, Leung PS. Potential roles of GPR120 and its agonists in the management of diabetes. Drug Des Devel Ther 8: 1013–1027, 2014.